Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody

  1. Sarah Cantor
  2. Wei Zhang
  3. Nicolas Delestrée
  4. Leonor Remédio
  5. George Z Mentis
  6. Steven J Burden  Is a corresponding author
  1. New York University School of Medicine, United States
  2. Columbia University, United States

Abstract

In amyotrophic lateral sclerosis (ALS) and animal models of ALS, including SOD1-G93A mice, disassembly of the neuromuscular synapse precedes motor neuron loss and is sufficient to cause a decline in motor function that culminates in lethal respiratory paralysis. We treated SOD1-G93A mice with an agonist antibody to MuSK, a receptor tyrosine kinase essential for maintaining neuromuscular synapses, to determine whether increasing muscle retrograde signaling would slow nerve terminal detachment from muscle. The agonist antibody, delivered after disease onset, slowed muscle denervation, promoting motor neuron survival, improving motor system output, and extending the lifespan of SOD1-G93A mice. These findings suggest a novel therapeutic strategy for ALS, using an antibody format with clinical precedence, which targets a pathway essential for maintaining attachment of nerve terminals to muscle.

Article and author information

Author details

  1. Sarah Cantor

    Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, United States
    Competing interests
    No competing interests declared.
  2. Wei Zhang

    Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, United States
    Competing interests
    No competing interests declared.
  3. Nicolas Delestrée

    Center for Motor Neuron Biology and Disease, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  4. Leonor Remédio

    Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1509-0024
  5. George Z Mentis

    Center for Motor Neuron Biology and Disease, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  6. Steven J Burden

    Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, United States
    For correspondence
    steve.burden@med.nyu.edu
    Competing interests
    Steven J Burden, holds a patent (#9,329,182) for 'Method of treating motor neuron disease with an antibody that agonizes MuSK'.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3550-6891

Funding

ALS Association

  • Steven J Burden

National Institute of Neurological Disorders and Stroke (R37 NS36193)

  • Steven J Burden

National Institute of Neurological Disorders and Stroke (RO1 NS078375)

  • George Z Mentis

National Institute of Neurological Disorders and Stroke (T32 NS86750)

  • Sarah Cantor

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jonathan Glass, Emory University, United States

Ethics

Animal experimentation: All procedures were approved and mice were maintained according to Institutional Animal Use and Care Committee (IACUC protocol number 160425) guidelines at NYU Medical School.

Version history

  1. Received: December 14, 2017
  2. Accepted: February 2, 2018
  3. Accepted Manuscript published: February 20, 2018 (version 1)
  4. Accepted Manuscript updated: February 20, 2018 (version 2)
  5. Accepted Manuscript updated: February 22, 2018 (version 3)
  6. Version of Record published: March 5, 2018 (version 4)
  7. Version of Record updated: June 7, 2018 (version 5)

Copyright

© 2018, Cantor et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,430
    views
  • 764
    downloads
  • 54
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sarah Cantor
  2. Wei Zhang
  3. Nicolas Delestrée
  4. Leonor Remédio
  5. George Z Mentis
  6. Steven J Burden
(2018)
Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody
eLife 7:e34375.
https://doi.org/10.7554/eLife.34375

Share this article

https://doi.org/10.7554/eLife.34375

Further reading

    1. Cell Biology
    2. Neuroscience
    Mariana I Tsap, Andriy S Yatsenko ... Halyna R Shcherbata
    Research Article Updated

    Mutations in Drosophila Swiss cheese (SWS) gene or its vertebrate orthologue neuropathy target esterase (NTE) lead to progressive neuronal degeneration in flies and humans. Despite its enzymatic function as a phospholipase is well established, the molecular mechanism responsible for maintaining nervous system integrity remains unclear. In this study, we found that NTE/SWS is present in surface glia that forms the blood-brain barrier (BBB) and that NTE/SWS is important to maintain its structure and permeability. Importantly, BBB glia-specific expression of Drosophila NTE/SWS or human NTE in the sws mutant background fully rescues surface glial organization and partially restores BBB integrity, suggesting a conserved function of NTE/SWS. Interestingly, sws mutant glia showed abnormal organization of plasma membrane domains and tight junction rafts accompanied by the accumulation of lipid droplets, lysosomes, and multilamellar bodies. Since the observed cellular phenotypes closely resemble the characteristics described in a group of metabolic disorders known as lysosomal storage diseases (LSDs), our data established a novel connection between NTE/SWS and these conditions. We found that mutants with defective BBB exhibit elevated levels of fatty acids, which are precursors of eicosanoids and are involved in the inflammatory response. Also, as a consequence of a permeable BBB, several innate immunity factors are upregulated in an age-dependent manner, while BBB glia-specific expression of NTE/SWS normalizes inflammatory response. Treatment with anti-inflammatory agents prevents the abnormal architecture of the BBB, suggesting that inflammation contributes to the maintenance of a healthy brain barrier. Considering the link between a malfunctioning BBB and various neurodegenerative diseases, gaining a deeper understanding of the molecular mechanisms causing inflammation due to a defective BBB could help to promote the use of anti-inflammatory therapies for age-related neurodegeneration.

    1. Neuroscience
    Mohsen Sadeghi, Reza Sharif Razavian ... Dagmar Sternad
    Research Article

    Natural behaviors have redundancy, which implies that humans and animals can achieve their goals with different strategies. Given only observations of behavior, is it possible to infer the control objective that the subject is employing? This challenge is particularly acute in animal behavior because we cannot ask or instruct the subject to use a particular strategy. This study presents a three-pronged approach to infer an animal’s control objective from behavior. First, both humans and monkeys performed a virtual balancing task for which different control strategies could be utilized. Under matched experimental conditions, corresponding behaviors were observed in humans and monkeys. Second, a generative model was developed that represented two main control objectives to achieve the task goal. Model simulations were used to identify aspects of behavior that could distinguish which control objective was being used. Third, these behavioral signatures allowed us to infer the control objective used by human subjects who had been instructed to use one control objective or the other. Based on this validation, we could then infer objectives from animal subjects. Being able to positively identify a subject’s control objective from observed behavior can provide a powerful tool to neurophysiologists as they seek the neural mechanisms of sensorimotor coordination.